中国 生物制药研发和产品周 - s3-ap-southeast-1 ...

[Pages:7]IBC LIFE SCIENCES

15 - 17 Hilton China

May 2018 Shanghai Hongqiao

SEE

Hotel,

REGISTRRAAATTTIETOSRN AAPAVCGATEIIVLFOAERBGDLREETO!AUILPS!

UNRIVALLED LINE-UP OF BIOPHARMA LEADERS

Zhihao (Peter) Qiu Branch Chief, Division of Inspectional Assessment Office of Process and Facilities, Office of Pharmaceutical Quality

CDER, FDA, U.S.

Andrew Huntley Senior Managing Director

BDA Partners, UK

Jerry Yang

Dong Huifang

SVP, Process & Product

Director of Cell Line Development

Development, Hangzhou JUST

WuXi Biologics, China

Biotherapeutics Co., Ltd., China

Xu Wei Vice President Manufacturing

Innovent Biologics, China

Bryan Kim Vice President of Business

Development Samsung Bioepis, Korea

Dr. Dennis Yu Xia Vice President of Manufacturing

and Quality Akeso Bio, China

Jiang Junjun Assistant Director WuXi Biologics, China

Minseob Lee Team Leader of R&D CMC/PM

Celltrion R&D, Korea

Yun Kang Vice President of Manufacturing

Generon Beijing, China

Yifang Wu President Wanbang Biopharmaceuticals Co., Ltd, China

Jian Dong Vice President & Site Head of

Manufacturing Wuxi AppTec, China

Dr. Jinyou Zhang Senior Vice President/Head, Bio Development and Manufacturing

BeiGene Co Ltd, China

Sunny Zhou Professor, Department of Chemistry and Chemical Biology Northeastern University, USA

Alvin Luk Senior Vice President and Chief Medical Officer ? Global Clinical

Operations and Affairs Shanghai Henlius Biotech Co

Ltd, China

Shaoqing Yang Vice President

Zhejiang Doer Biologics Co., China

Zack Zheng, Ph.D. VP of Process Development

(Wuhan) JHL BioTech, China

Prof. David James University of Sheffield, UK

Dr Jun Yuan Vice President Quacell Biotech, China

Dr. Jacqueline Ming Liu Vice President

TOT Biopharma, China

Prof. Dr. Florian Turk Head Global Payor Marketing,

Sales and Relations Sandoz Biopharmaceuticals Sandoz International GmbH,

Germany

Dr Xin Zhang Vice President of Global Clinical

Operations and Affairs Shanghai Henlius Biotech, Inc.,

China

Sam Zhang Senior Principal Scientist/Group Leader, Cell Line Development,

Bioprocess R&D Pfizer Inc, USA

Dr Qiwei Wu, Ph.D Vice President of Process Development and Manufacturing Livzon Mabpharma, China

Ng Say Kong Staff Scientist, Animal Cell Technology 2, Bioprocessing

Technology Institute A*STAR, Singapore

CHINA'S LEADING AND MUST ATTEND BIOPHARMA EVENT WITH QUALITY CONTENT & EXCELLENT PLATFORM TO NETWORK WITH LEADERS OF THE INDUSTRY

BDP CHINA 2018 STRONG VALUE PROPOSITION

3

CO-LOCATED CONFERENCES WITH INTERACTIVE

SESSIONS

300+

SENIOR PHARMA ATTENDEES

60+

EXPERT SPEAKERS

60+

MARKET FACING SESSIONS



1

JOINT EXHIBITION & NETWORKING AREA

MAIN CONFERENCE DAY ONE - WEDNESDAY, 16 MAY 2018

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS

08:00 Main Conference Registration and Morning Coffee

08:50 Welcome Address from IBC Asia

09:00 Chairperson's Opening Remarks

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

09:10 Global and Local Biopharma Market Trends and Implications

? Innovation in biopharma pipelines ? what can we expect ? Recent regulatory developments ? obstacle or opportunity? ? How digitalisation of BioPharma is creating new value propositions ? Biomanufacturing market snapshot in China ? Biosimilars market potential ? what can we achieve? ? New trends in cell line development Moderator: Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China

Panellists: Jerry Yang, SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China Xu Wei, Vice President, Manufacturing, Innovent Biologics, China Xiao Zhi Hua, Chief Executive Officer, OPM Biosciences, China Jun Liu, Vice President, TOT Biopharma, China Yanshan Huang, Chief Executive Officer, DOER Biologics, China

10:10 Global M&A Trends and Deal Flow in the Outsourced Pharma Manufacturing Services Sector

Andrew Huntley, Senior Managing Director, BDA Partners, UK

10:50 Morning Networking & Refreshment Break

11:20 Chairperson's Opening Remarks

Xu Wei, Vice President, Manufacturing, Innovent Biologics, China

THE MARKETING AUTHORIZATION HOLDER (MAH) REGIME

11:25

Overview of Biotech Product Manufacturing-A Regulatory Perspective

Zhihao(Peter) Qiu, Branch Chief, Division of Inspectional Assessment, Office of Process and

Facilities, Office of Pharmaceutical Quality, CDER, FDA, U.S.

11:55

Industry Panel: Striving to Achieve Nationwide Implementation of the MAH Regime- What Can we Expect?

Moderator: Xu Wei, Vice President, Manufacturing, Innovent Biologics, China Jerry Yang, SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd. China Zhihao(Peter) Qiu, Branch Chief, Division of Inspectional Assessment, Office of Process and Facilities, Office of Pharmaceutical Quality, CDER, FDA, U.S. Zack Zheng, Ph.D. VP of Process Development (Wuhan), JHL BioTech, China

CAS E STUDY

UTILITY EFFICIENCY AND OPTIMIZATION

13:30 A Case Study on Setting Up Merck's E2E Biodevelopment Center in Shanghai

Aurore Lahille, Head of EMEA E2E Process Development, Merck, France

14:00 Optimising Continuous Process with Smart Technologies

Swee Nguan Lim, Director of Asia Pacific Sales, Finesse, part of Thermo Fisher Scientific, Singapore

14:30 Case Study: Building a WorldClass Highly Flexible Continuous Manufacturing Facility and Quality System in China

Dr. Frank Ye, SVP of Manufacturing and Quality, Hangzhou Just Biotherapeutics Co., Ltd., China

CAS E STUDY

11:20 Chairperson's Opening Remarks

Sunny Zhou, Professor, Department of Chemistry and Chemical Biology, Northeastern University, USA

CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND STABILITY

11:30

Generation of Unique Clone Fingerprints for Control and Enhancement of CHO Cell Factories

Jerry Clifford, Chief Operating Officer, Valitacell, Ireland

12:00 Using Nanoscale Bioreactors To Select Top CHO Clones and Predict Stability in 5 Days

Keith Breinlinger, Chief Technology Officer, Berkeley Lights Inc.

12:30 Networking Lunch

ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES

13:40 Applications of a New All-in-One Seeding and Imaging System in the Rapid Establishment of Monoclonal Cell Lines

George Hutchinson, Head of Global Distribution, Solentim, UK

14:20 Highly Productive Cell Line Development Platform

Eric Chang, Head of Cell Line Development, JHL Biotech, Taiwan

11:10

Chairperson's Opening Remarks

Dr. Ming Wang, President and Chief Executive

Officer, Phanes Biopharmaceuticals, China

CHINA'S BIOSIMILARS MARKET

11:10 Nutritional Levers for Biosimilarity

Dr. Ryan Karcher, Senior R&D Scientist & Team

Lead, Merck, U.S

CAS E STUDY

11:40

The Importance of Media and Supplements in Two Biosimilar CHO Cell Lines

Henry Zhang, APAC Technical Application Representative, Kerry Inc., China

12:10

China Market Insight: Market Outlook

and Update on Biosmilars Pipelines

Dr. Scott Liu, President and CEO, Shanghai Henlius Biotech Inc., China

13:30 China Market Insight: Market Growth and Opportunities in Therapeutic Biosimilars

Xiao Zhi Hua, Chief Executive Officer, OPM Biosciences, China

14:00 Managing Costs and Technology Adoption in Biosimilar Development

Dr. Manfred Weiler, Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK

14:30 Biosimilars Development in China: Challenges in Bevacizumab Clinical Trial Design

Dr. Jacqueline Ming Liu, Vice President, TOT Biopharma, China

15:30

Case study: Scale-up of Continuous

Capture Chromatography

Johnson David M, Senior Global Product Manager, Continuous Purification, Pall Life Sciences, U.K.

16:00 Innovation in Chromatograpy Platform: Lattice Supported Modular Chromatography using Conventional Resin Enabling Flexible Operations, Linear Scalability & Hyper-Productive Processes

Masayoshi Nagaya, Sr. Global Technology Manager, JSR Life Sciences, US

16:30 Current Challenges of Biologics

Manufacturing in China

Xu Wei, Vice President, Manufacturing, Innovent Biologics, China

17:00 Efficacy of Insulation Systems in Aseptic areas and facilities: A Practical Guide to Facility Cost Reduction

David Sadler, President & CEO, Kunshan Zotek Kinglai Co. Ltd. U.K.

17:30

From Process Development to cGMP

Manufacturing - Process Control Strategy

Zack Zheng, Ph.D. VP of Process Development (Wuhan), JHL BioTech, China

15:00 Afternoon Networking & Refreshment Break

15:30 One Step Approach of Scale-Up in Process Development

Dr Jun Liu, Vice President, TOT Biopharma, China

QBD, PAT AND EARLY INTERVENTION STRATEGIES

16:00 Improving Late-Stage Product Quality Through Early Cell Culture Intervention

Sunny Zhou, Professor, Department of Chemistry and Chemical Biology, Northeastern University, USA

16:30 Glycans Before Lunch: Rapid N-Glycan Sample Preparation Workflows for Liquid Chromatography and Capillary Electrophoresis Platforms

Dr. John Yan, Applications Scientist, ProZyme, USA

QUALITY AND SIMILARITY ASSESSMENT

15:30 Biosimilar Clinical Materials: Changes

and Comparability

Dr Qiwei Wu, Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma, China

FIRESIDE CHAT

16:10

Fireside Chat: Analytical and Quality Assessment of Biosimilars

Interviewer:

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China Interviewee:

Dr Amy Hong Que, Vice President ? Quality, Innovent Biologics, China

16:40 End of Day Round-up Q&A session

17:00 A Quality by Design (QbD) Approach for Early Stage Cell-Culture Process Development

Hung Fai Poon, President, Quacell Biotech, China

17:30 Glycosylation Analysis and Control for

Improved Product Quality

Julie Wei, Director, JUST Biotherapeutics, China

17:55 Chairperson's Summary and End of Main Conference Day One followed by Networking Cocktail



MAIN CONFERENCE DAY TWO - THURSDAY, 17 MAY 2018

09:00 Chairperson's Opening Remarks

Yun Kang, Vice President of Manufacturing, Generon Beijing, China

INNOVATIONS IN MANUFACTURING SCIENCE AND TECHNOLOGY

09:00 Expediting the Process from CMC Development to Multi-Region Clinical Trials

Yun Kang, Vice President of Manufacturing, Generon Beijing, China

09:20 Rapid Microbiological Methods: Current Endotoxin/Sterility/Bacterial ID Applications in Bio Pharmaceutical Operations

John Dubczak, Director of Operations, Charles River Laboratories, U.S.

09:50 Multi-column, Parallelized Unit Operations Using a Single-Skid for Intensified DSP at Pilot Scale

Nicolas-Julian Hilbold, DSP Innovation Specialist, Merck KGaA (sponsored by Novasep)

10:20 New Challenge by Samsung BioLogics in Biopharmaceutical Development and Manufacturing

Eun Young Yang, Executive Director, Head of CDO Business Development Team, Samsung BioLogics, Korea

09:00 Chairperson's Opening Remarks

Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS

9:10 Liquid Engineering: CHO Cell Culture Performance Enhancement Using Small Molecules

Prof. David James, University of Sheffield, UK

9:40

Engineering a Fully Human HEK293 System for the High Titer Production of Recombinant Glycoprotein

Ng Say Kong, Staff Scientist, Animal Cell Technology 2, Bioprocessing Technology Institute, A*STAR, Singapore

10:10

Progressing Tech-Transfer and Cell

Culture Scale-Up for Biotherapeutics

Zhiwei Pan, Senior Director of Process Development, Livzon Mabpharm, China

09:00 Chairperson's Opening Remarks

Dr. Alvin Luk, Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

GOING GLOBAL AND PARTNERSHIPS

09:10 Opening Address: Key Learnings from a Global Perspective: How to Unlock the Full Potential of Biosimiliars ? Learnings from EU on Access and Procurement

Prof. Dr. Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

CAS E STUDY

09:40 Case Study: Global Development Strategy on Biosimilars: How to Win in the International Space

Pearl Fong, Associate Vice President, Division of Project Development, Mycenax Biotech Inc.,Taiwan

CAS E STUDY

10:10

Biopharma's Case Study: Perspective on Biosimilars Market Development, and China Market Potential and Partnerships

Bryan Kim, Vice President of Business Development, Samsung Bioepis, Korea

10:40 Morning Networking & Refreshment Break

COLD CHAIN MANAGEMENT

11.10 Designing and Developing a Quality Driven Process to Mitigate Risk in Delivering Temperature Sensitive Biopharmaceuticals to Market

Iris Desiree Sioson, Reliability Manager, APAC, Envirotainer, Singapore

QUALITY COMPLIANCE AND SYSTEM

11:40

Strategic Practice in Building Quality Management Systems (QMS) in China Facilities

Dr. Dennis Yu Xia, Vice President of Manufacturing and Quality, Akeso Bio, China

THERAPEUTIC MAB INNOVATION AND DISCOVERY

11.10 Design Novel Polyagonist Drugs forObesity & Type II Diabetes

Shaoqing Yang, Vice President, Zhejiang Doer Biologics Co., China

NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION SYSTEMS

11.40

Fireside Chat: Manufacturing Stable Expression Platforms by Gene Engineering Technology

Interviewer: Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Inc, USA Interviewee: Wang Tong Ying, Chief Technical Officer, Hangzhou Jiuyuan Gene Engineering, China

SAFETY AND EFFICACY

11:10

A Biopharma Solution for Automated

Glycan Characterization

Dr. Sven Bahrke, Senior Director Cooperations, Glycotope GmBH, Germany

11:40

The Long and Winding Road: Operational

Challenges for Biosimilar Clinical Trials

Dr Xin Zhang, Vice President of Global Clinical Operations and Affairs, Shanghai Henlius Biotech, Inc., China

12:10 Networking Lunch

13:10

The Practice and Challenge of MAH Pilot Program under Current CFDA Regulation

Dr. Jiali Luo, General Manager, Boehringer Ingelheim Biopharmaceuticals, China

FACILITIES AS COMPETITIVE ADVANTAGE

CAS E STUDY

13:50

Case Study: Building a WHO PQ

Compliant New Facility

Dr. John Zeng, Executive Vice President, Bioprocess Development & Pilot Plant Manufacturing Shanghai Zerun Biotech Co Ltd, China

14:30 GMP Biomanufacturing Facility Design and Operation ? Cultural Clash Between East and West

Dr. Jinyou Zhang, Senior Vice President/Head, Bio Development and Manufacturing, BeiGene Co. Ltd., China

15:10

Microbial Control During Biologics

Manufacturing

Hui Cai, Head of QC Laboratory 2 & Head of Microbial Control Team, WuXi Biologics, China

13:10

Panel Discussion: Next Generation Non-CHO Expression Systems for Novel Biotherapeutic Applications

Moderator: Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA Panellists: Dong Huifang, Director of Cell Line Development, WuXi Biologics, China Dr Jun Yuan, R&D Director, Quacell Biotech, China Sai Ling Liu, Product Development Expert, Surfer Biotech, China

14:00 Aiming for High Productivity and Stability in the Era of CHO Genome

Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D,

Pfizer Inc, USA

14:40 Challenges & Opportunities of

Biotherapeutic Glcosylation

Zhou Hui, Chief Executive Officer, Glycogene Biotherapeutics, China

15:10

Rapid Protein Production in CHO Cells:

From Transfection to 100 g in 6 Weeks

Dong Huifang, Director of Cell Line Development, WuXi Biologics, China

COMMERCIALISATION OF BIOSIMILARS

CAS E STUDY

13:10

Biopharma's Case Study: Remsima? Success Story and Strategy to Overcome Hurdles, Move into Mainstream

MinSeob Lee, Team Leader of R&D CMC/PM, Celltrion R&D, Korea

14:00 Commercialization Practicality: CFDA's Requirement on `Biosimilar Application and RA Operation Support Model

Eric Liu, China Biosimilars Regulation Publishing Manager, Pfizer, China

14:50 Applying High Throughput Process Development Platform to Develop Downstream Process for Clinical Manufacturing

Jiang Junjun, Assistant Director, WuXi Biologics, China

15:40 Afternoon Networking and Refreshment Break

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 CLOSING PLENARY SESSIONS

16:20

BDP China 2018 Round Up Panel: A vision for China's Biopharma Industry in the Next Decade

? Enabling drivers of innovation in China ? Consolidation of local players ? Shifting investment from manufacturing focus to innovative portfolios ? Adopting technologies that enable the potential in manufacturing, cell

development and similarity ? Attracting the right talent

Moderator: Yun Kang, Vice President of Manufacturing, Generon Beijing, China Panellists: Zheru Zhang, President, I-Mab Biopharma, China Dr. Alvin Luk, Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China Shaoqing Yang, Vice President, Zhejiang Doer Biologics Co., China

17:00 Chairperson's Summary of the Day and End of Conference

Session outline may change to accomodate market-specific or company development.



PRE-CONFERENCE WORKSHOPS TUESDAY 15 MAY 2018

9.00AM - 4.40PM

PALL CONTINUOUS BIOPROCESSING WORKSHOP

Daniel Ming Yuan, Biotech Business Unit

GM, Pall China

Jun Wang, Ph.D., Marketing Manager, Biotech BU, Pall China

Schofield Mark., Senior Manager, R&D

Workshop Leaders:

Johnson David M., Senior Global Product Manager, Continuous

Purification

Peter Shen, VP, Process Development & Clinical Manufacturing, WuXi

Biologics, Inc

Meng Yang, Senior Technical Manager, Biotech BU, Pall China

Tao Shi, Senior SLS Manager, Biotech BU,

Pall China

AGENDA AT A GLANCE:

9.00AM - 1.00PM 1. INTEGRATED PROCESS DEVELOPMENT AND PROTEIN ANALYTICS TO IMPROVE BIOSIMILARITY

Yunfen He, Senior Director, OPM Biosciences

2. QUALITY CONTROL & CHARACTERIZATION IN ANTIBODY DRUGS DEVELOPMENT

Zhigui Zhou, Director, OPM Biosciences

3. KEY CONSIDERATIONS IN PK OF BIOSIMILAR DEVELOPMENT

Lihou Dong, Senior Director, United-Power Pharma

EXPLORE MAH REGIME FOR BOTH PHARMA AND CMOS IN CHINA

DISCOVER APPLICATION OF NEW DISRUPTIVE TECHNOLOGIES AND

IMPROVEMENT ON PROCESS DEVELOPMENT

GLOBAL TRENDS IN FACILITIES OF THE FUTURE

SINGLE USE SYSTEMS

NEW CASE STUDIES ON ACHIEVING OPERATIONAL, QUALITY AND COST

EFFECTIVENESS

COMPLIANCE IMPROVEMENTS AND HOW TO GET CLOSER TO FDA

EXPECTATIONS

CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND

STABILITY

ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES

OVERVIEW OF THE GLOBAL BIOSIMILARS MARKET AND OUTLOOK

EXPLORE GLOBAL MARKET POTENTIAL AND PARTNERSHIPS

STRATEGY

QBD, PAT AND EARLY INTERVENTION STRATEGIES

EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS

THERAPEUTIC MAB INNOVATION AND DISCOVERY

NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION

SYSTEMS

PROCESS, RESTRICTIONS AND GUIDELINES TO GAIN REGULATORY

APPROVAL

ASSESS QUALITY AND SIMILARITY OF BIOSIMILARS

SAFETY, EFFICACY AND RISK CONSIDERATION

COMMERCIALIZATION OF BIOSIMILARS ? CHALLENGES AND

OPPORTUNITIES

"IT'S A WONDERFUL MEETING AND I OBTAINED MUCH MORE KNOWLEDGE AND I RECOMMEND IT NEXT YEAR"

Senior Medical Manager, Shanghai Hengrui Pharmaceutical Co., Ltd

Media Partners:

Supporting Association:



The Biopharma Development & Production Week hosts China's key biopharma leaders and international experts, prides itself as a leading industry platform for its practical contents, quality of sessions, excellent networking platform and THE gathering place for pharma, biotech, CMOs, CROs, research institutes, investors, technology and industry stakeholders.

WHO SHOULD ATTEND:

? Chief Executive Officer

? Chief Operations Officer

? Chief Scientific Officer

? Chief Technology Officer

? Business Development and Marketing

? Head of Analytics

? Head of Cell Line Development

? Head of Manufacturing, Bioprocessing, Operations

? Head of Process Sciences and Manufacturing

? Head of Quality Assurance & Quality Control

? Principal Scientist

? USP & DSP Specialists

? VPs & Directors of Biosimilars

? VPs & Directors of Process Development

? VPs & Directors of R&D

MEET YOUR TARGET AUDIENCE: BY COUNTRY:

60% China

15%

Other Asian Countires

10% US

5%

Other Regions

10% Europe

BY INUSTRY:

Pharma/Biopharma/Biotech....................................... 55% CMO/CRO...............................................................................10% Government Agencies..........................................................2% Laboratory Equipment & Technology.......................... 4% Industry & Laboratory Chemicals....................................3% Pharma Construction & Engineering Services.......... 1% Cold Chain Supplies............................................................. 4% Academics/Research Institutes/Consultancy........... 1% Other Service Providers.................................................... 20%

WHAT PAST ATTENDEES SAID:

"GREAT EVENT WITH LOTS OF INSIGHTS ON CHINESE MARKET AND DEVELOPERS. MET MANY GREAT PEOPLE."

Tucker Herbert, Manager, ZS Associates

"WELL ORGANIZED, EXPANDING THE VISION OF THE BIO INDUSTRY IN DIFFERENT COUNTRIES IN ASIA."

Jinhua Zhang, Business Development Director, Livzon MabPharm

"IT'S QUITE MORE PROFESSIONAL THAN NORMAL COMMERCIAL CONFERENCE."

Yunxia Xu,PM,Centergene



SPONSORS AND EXHIBITORS:

GOLD SPONSORS:

BRONZE SPONSORS:

ASSOCIATE SPONSOR:

SESSION SPOTLIGHT SPONSORS: EXHIBITORS:

EXHIBITION FLOORPLAN:

Host Lucky Draws During the

Networking Breaks

WIFI Sponsor

Area

10 9 8

1

7

Exclusive Sitting Lunch Room Available for Sponsorship

Buffet 14

13

15 16 17 18

12 3

19 20

37

11 2

36

38

35

39

34

40

41

27 28

33 32

6

26

29

25

30

24 23

31

5

22

Exclusive Sponsor Meeting Rooms Available Upon Request 21

Entrance

8

4

9

=VIP

INTERACTIVE COMMON AREA FOR

EXHIBITION AND REFRESHMENT BREAKS

SPONSORSHIP OPPORTUNITIES

Sponsorship opportunities are now also available. To position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available, please contact: Ms. Yvonne Leong at Tel: +65 6508 2489 l Email: Yvonne.Leong@.sg



If undelivered, please return to:

111 Somerset Road, TripleOne Somerset #10-05, Singapore 238164 Tel: +65 6508 2400 Fax: +65 6508 2407

BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

ATTRACTIVE GROUP DISCOUNTS

AVAILABLE!

SPECIAL RATES FOR LOCAL CHINA

COMPANIES!

RESERVE YOUR PLACE TODAY!

Yes! I/We will attend Biopharma Development & Production Week, 15-17 May 2018 I cannot attend this event but please include me on your mailing list I would only like to purchase the conference documentation at SGD1,000 / SGD1,070 (with 7% GST) per set

INTERNATIONAL COMPANIES - OUTSIDE CHINA

Fee Per Delegate

Early Bird Rate Register & pay on or before

16 March 2018

Normal Rate Register & pay after

16 March 2018

2 Day Package 2 Day Conference (16-17 May 2018)

USD 1,695

ADD ON WORKSHOP: USD 300 per workshop per delegate ? Pre-conference workshop (15 May 2018)

LOCAL CHINA COMPANIES

USD 1,895

Group Rate (2 or more Delegates)

Group Rate (4 or more Delegates)

Applicable across 3 events, only on 2-day main conference package

USD 1,495

USD 1,295

2 Day Package 2 Day Conference (16-17 May 2018)

CNY 5,500

ADD ON DAY: ADD CNY 1,000 (Pre Conference Workshop) ? Pre-conference workshop (15 May 2018)

CNY 6,500

CNY 5,000

CNY 4,500

? Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.

? All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel. ? Registration fees are subject to the prevailing government tax

Delegate 1 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Delegate 3 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Who is Head of your Department? Who is Head of Training? Company Name: Address:

Delegate 2 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Delegate 4 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email:

Main Business/Activity: Postal Code:

(Please photocopy for additional delegates)

Payment Method (Please tick:)

I enclose my Cheque/Draft payable to IBC Asia (S) Pte Ltd

I am paying by bank transfer (copy attached)

Payment by Credit Card: Visa Mastercard Amex

Credit Card Payments The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at and click "Register On-line". If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confi dence, please do not send payment details by email.

Credit card contact:: Direct phone number:

Department: Email:

P46350

(Please provide photocopy of front & back of your Credit Card)

5 EASY WAYS TO REGISTER

MAIL the attached registration form with your cheque to IBC Asia (S) Pte Ltd c/o Informa Regional Business Services 111 Somerset Road, TripleOne Somerset #10-05, Singapore 238164

Customer Service Hotline +65 6508 2401

Email register@.sg

Fax +65 6508 2407

Web

HOTEL INFORMATION

Hilton Shanghai Hongqiao 1116 Hong Song East Road Shanghai 201103 China Telephone: +86 21 3323 6666 Fax: +86 21 3323 6999 Hotel Website: shanghaihongqiao.

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date. All payments should be made in Singapore dollars.

Payments by S$ bank draft or cheque should be made in favour of "IBC Asia (S) Pte Ltd" and mailed to:

IBC Asia (S) Pte Ltd c/o Informa Regional Business Services 111 Somerset Road TripleOne Somerset #10-06 Singapore 238164 Attn: The Accounts Receivable Team

Payment by telegraphic transfer in S$ must be made to:

IBC Asia (S) Pte Ltd A/CNo.: 147-059513-001 (SGD) The Hongkong and Shanghai Banking Corporation Limited 21 Collyer Quay, HSBC Building, Singapore 049320 Bank Swift Code: HSBCSGSG Bank Code: 7232

Payment by Credit Card (AMEX, VISA or MASTERCARD).

Please provide your Card Number, Name of Cardholder, Expiry Date and Signature and send it by fax to +65 6508 2407.

CANCELLATIONS / SUBSTITUTION

Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.

IMPORTANT NOTE

Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407).

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC.

DATA PROTECTION

The personal information entered during your registration/ order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please contact our Database Department at Email: database@.sg, Tel: +65 6508 2400 or Fax: +65 6508 2408.

REG NO. 200108203N

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download